Georgia State University Sep 3 2024 Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, who are at greatest risk of developing severe COVID-19, according to researchers in the Center for Translational Antiviral Research at Georgia State University's Institute for Biomedical Sciences.  While best to begin treatment earlier, in immunocompromised hosts, drugs like paxlovid and molnupiravir appear to

Tag-uri: Coronavirus